看過這個麽

來源: 2020-12-14 09:09:21 [博客] [舊帖] [給我悄悄話] 本文已被閱讀:

https://www.tandfonline.com/doi/full/10.1080/13102818.2020.1775118

Conclusions

The available pharmacokinetic data for ivermectin indicate that at the doses routinely used for the management of parasitic diseases the SARS-CoV-2 inhibitory concentrations are practically not attainable. At present any empiric treatment with ivermectin or its inclusion in therapeutic protocols are not scientifically justifiable. The very consideration of the drug as a broad spectrum antiviral agent is incorrect because it has failed to demonstrate antiviral effects beyond the in vitro level. Pending the paucity of reliable data from controlled studies and the aforementioned pharmacokinetic considerations, the application of ivermectin in COVID-19 patients is to be decisively discouraged.

 

還有,FDA這麽說的:

https://www.fda.gov/emergency-preparedness-and-response/coronavirus-disease-2019-covid-19/covid-19-frequently-asked-question